Novo Nordisk A/S - Share Repurchase Programme

Bagsværd, Denmark, 13 January 2025 – On 11 November 2024, Novo Nordisk announced the start of a share repurchase programme. This initiative complies with Article 5 of Regulation No 596/2014 from the European Parliament and Council dated 16 April 2014, known as MAR (Market Abuse Regulation), along with the Commission Delegated Regulation (EU) 2016/1052 from 8 March 2016, which encompasses the "Safe Harbour Rules." The programme is designed to repurchase shares worth up to DKK 20 billion over a span of 12 months, commencing from 6 February 2024.

Specifically, for the programme launched on 11 November 2024, Novo Nordisk plans to buy back B shares totaling up to DKK 3,136,206,122.30, which will occur between 11 November 2024 and 3 February 2025.

Following the announcement made on 20 December 2024, Novo Nordisk has conducted the following transactions:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,311,875		1,748,331,923
2 January 2025	96,000	636.79	61,132,013
3 January 2025	94,334	632.25	59,642,769
6 January 2025	95,000	623.96	59,276,145
7 January 2025	96,000	604.45	58,027,107
8 January 2025	100,000	618.34	61,833,956
9 January 2025	97,126	625.92	60,792,638
10 January 2025	99,932	633.15	63,272,401
Accumulated under the programme	2,990,267		2,172,308,952

The complete details of each transaction made under this share repurchase programme are available on the official Novo Nordisk website.

As it stands, with the recent transactions, Novo Nordisk holds a total of 24,337,924 B shares valued at DKK 0.10 as treasury shares, representing 0.5% of its total share capital. The company currently has a total of 4,465,000,000 A and B shares, which includes the treasury shares.

Looking ahead, Novo Nordisk anticipates repurchasing B shares amounting to up to DKK 20 billion throughout the specified 12-month period starting from 6 February 2024. By 10 January 2025, since the beginning of this repurchase plan, the company has successfully bought back a total of 23,193,366 B shares at an average purchase price of DKK 820.76 each, totaling a transaction value of DKK 19,036,102,830.

Novo Nordisk is a prominent global healthcare company that was founded in 1923 and has its headquarters in Denmark. The company aims to make a difference in combating significant chronic diseases, with a strong focus on diabetes. They achieve this by pioneering scientific advancements, enhancing access to their products, and striving to prevent and ultimately find cures for diseases. Novo Nordisk employs around 72,000 people across 80 countries, marketing its products in approximately 170 countries. The company’s B shares are traded on Nasdaq Copenhagen (Novo-B), and its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange (NVO). For more information, please visit their official website or follow them on social media platforms.

For further inquiries, please contact:

Media:
Ambre James-Brown +45 3079 9289 [email protected]	Liz Skrbkova (US) +1 609 917 0632 [email protected]
Investors:
Jacob Martin Wiborg Rode +45 3075 5956 [email protected]	David Heiberg Landsted +45 3077 6915 [email protected]
Sina Meyer +45 3079 6656 [email protected]	Ida Schaap Melvold +45 3077 5649 [email protected]
Frederik Taylor Pitter +1 609 613 0568 [email protected]

This announcement is identified as Company announcement No 1 / 2025.

Novo, Nordisk, Shares